Global MarketsDURECT outlines $20M Section 3 trial for larsucosterol in alcohol-associated hepatitis By StockWaves Last updated: March 27, 2025 0 Min Read SHARE DURECT outlines $20M Section 3 trial for larsucosterol in alcohol-associated hepatitis Sign Up For Daily NewsletterBe keep up! Get the latest breaking news delivered straight to your inbox. Leave this field empty if you're human: By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time. Share This Article Facebook Twitter Copy Link Print Previous Article Breakout shares to purchase or promote: Sumeet Bagadia recommends 5 shares to purchase at present — 27 March 2025 Next Article Gynecological Cancers in India Anticipated to Rise by 55% by 2040; Specialists Name for Pressing Motion and Preventive Measures Leave a commentLeave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment *Name * Email * Website Save my name, email, and website in this browser for the next time I comment. FacebookLikeTwitterFollowPinterestPinInstagramFollowSubscribe NowSubscribe to our newsletter to get our newest articles instantly! Leave this field empty if you're human: Most Popular COMTEX | PRESS RELEASE DISTRIBUTION & NEWS API April 30, 2025 Glad U Got here Strengthens Management Crew with Strategic Appointments April 30, 2025 5 Shares to purchase now for an upside potential of as much as 31%; Do you personal it? April 30, 2025 Ternium studies Q1 outcomes April 30, 2025 Forms of mutual funds defined April 30, 2025
